US › Healthcare

Innate Pharma (IPHA)

US · Healthcare · Biotechnology

$1.78+3.78%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$-2.1M
Revenue YoY
-116.8%
Net profit
$-27.6M
Profit YoY
-11.6%
EPS
$0.00
EPS estimate
$-0.16
Net margin
1,332.7%

EPS came in at 0.00 against a street estimate of -0.16 — a beat of 100.0%.

Key statistics

Market cap
$161.5M
Forward P/E
0.0
P/B
20.10
Book value
$-0.27
EPS (TTM)
$-0.63
52-week high
$2.62
52-week low
$1.17
50-day MA
$1.80
200-day MA
$1.73
Beta
0.86

Analyst view

Analysts rate Innate Pharma a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $6.00.

Shareholding

Insiders
1.67%
Institutions
0.45%

Largest institutional holders

FundStake
Lion Point Capital, LP0.09%
Morgan Stanley - Brokerage Accounts0.05%
Jane Street Group LLC0.05%
Millennium Management LLC0.01%
Rhumbline Advisers0.01%
UBS Group AG0.00%
GAMMA Investing LLC0.00%
Caitong International Asset Management Co., Limited.0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Innate Pharma — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.